Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 16/20 | 0.45 |
| ▸ | PGR | P06401 | 8/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5865893 | 0.86 | PARG (0.50) | PARGARPGRPIK3CGNR3C1 | |
| SCHEMBL6022453 | 0.86 | AR (0.48) | PARGARPGRPIK3CGNR3C1 | |
| SCHEMBL6023005 | 0.86 | PIK3CG (0.57) | PARGARPGRPIK3CGNR3C1 | |
| SCHEMBL5865896 | 0.84 | AR (0.47) | PARGARPGRPIK3CGNR3C1 | |
| SCHEMBL26090948 | 0.81 | PARG (0.64) | PARGTP53PIK3CG | |
| SCHEMBL5865901 | 0.79 | HSD17B10 (0.57) | ARTP53 | |
| SCHEMBL5865914 | 0.79 | HSD17B10 (0.57) | ARTP53 | |
| SCHEMBL6022431 | 0.78 | BRD1 (0.61) | PARGTP53MAPT | |
| SCHEMBL6022392 | 0.78 | POLB (0.49) | PARGPGRNR3C1 | |
| SCHEMBL5865870 | 0.77 | ALDH1A1 (0.45) | PARGARPGRNR3C1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064207-B2 | 6-sulfonamido-quinolin-2-one and 6-sulfonamido-2-oxo-chromene derivatives, useful for treating alopecia, acne and oily skin | WARNER LAMBERT COMPANY LLC (US) | 2006-06-20 | — | — | US | disclosed |
| US-7009052-B2 | Sulfonamide derivatives | WARNER LAMBERT COMPANY LLC (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050085467-A1 | Androgen receptor antagonists | DU DANIEL Y (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050004367-A1 | Sulfonamide derivatives | DU DANIEL Y (US) | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085467-A1 | Androgen receptor antagonists | AR, NR5A1, ESRRB | PARG 4544/4885AR 1/4885PGR 100/4885 |
| US-20050004367-A1 | Sulfonamide derivatives | AR, SULT2A1, SHBG | PARG 4609/4885AR 1/4885PGR 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.